Protocol No.: MK1045-005

A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Principal Investigator
Emadi, Ashkan
Phase
II/III
Age Group
Adult
Applicable Disease Site
Leukemia
Participating Institution
Contact
Abby Swiger, RN
Research Nurse
Phone: +1 304-293-1683